NetworkNewsBreaks – Caladrius Biosciences, Inc. (NASDAQ: CLBS) Receives “Buy” Rating, $15 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $15 on shares of Caladrius Biosciences’ (NASDAQ: CLBS) stock. The company recently reported financial results for the three and 12 months ended December 31, 2016. The company full year revenues of $35.3 million, an increase of 57% compared with $22.5 million for 2015. Caladrius also reported cash at year-end of $14.7 million. Additionally, the company recently announced the sale of the remaining 80.1% interest in its PCT LLC subsidiary to Hitachi Chemical for $75 million in cash with an additional $5 million payable upon reaching an undisclosed revenue milestone by the end of 2018. Caladrius said it is now shifting its focus to the development of cell-based therapies.

For more information visit www.caladrius.com

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. Caladrius has entered into a definitive agreement pursuant to which Hitachi America intends to purchase Caladrius’ remaining 80.1% membership interest in PCT and thereby transform Caladrius into a therapeutics-only development company. The sale of the company’s remaining interest in PCT is subject to the approval of the company’s stockholders and customary closing conditions. There can be no assurance that such sale will be completed in the anticipated timeframe or at all.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s